Overview of Climesse

Climesse is a continuous combined Hormone Replacement Therapy (HRT) tablet designed for oral administration in postmenopausal women with an intact uterus.

Property	Description
Active ingredient	Estradiol (Oestrogen) and Norethisterone (Progestogen)
Form	Oral tablet (Film-coated tablet)
Pharmacological class	Oestrogen-Progestogen Therapies; HRT
Legal Status	Prescription-only medicine (-only)
Regimen Type	Continuous Combined (daily, non-cyclical)

What Type of Medicine is Climesse?

Climesse is formally classified as an oral Hormone Replacement Therapy (HRT), which falls under the Oestrogen-Progestogen Therapies pharmacological class. This combination product is supplied as a film-coated tablet and utilizes a Continuous Combined Regimen, meaning both hormonal components are taken daily without interruption. The continuous nature of the regimen is a differentiating feature, providing consistent hormone levels which often eliminates the withdrawal bleeding associated with sequential HRT types. It is strictly a prescription-only medicine.

Climesse Active Ingredients: Estradiol and Norethisterone

The core of Climesse is its fixed-dose combination of two active ingredients: Estradiol and Norethisterone. Estradiol serves as the oestrogen component and is a structural analogue of the primary endogenous natural female hormone. This oestrogen is administered to achieve systemic substitution. Norethisterone functions as the progestogen component, which is a synthetic progestogen (a 19-nortestosterone derivative) included to balance the effects of the oestrogen.

What is the General Purpose of This Combination HRT?

The general purpose of Climesse is to provide Hormone Substitution to address the physiological consequences arising from oestrogen deficiency following menopause. The Estradiol component substitutes for the diminished endogenous hormone supply. While the Estradiol addresses deficiencies, the concurrent use of Norethisterone is critical because it provides essential endometrial protection. This combined approach ensures the therapeutic goal of oestrogen replacement is achieved while mitigating risks associated with unopposed oestrogen stimulation of the uterine lining. Consequently, the combination product is used for its intended target audience: postmenopausal women with an intact uterus.

What side effects are possible with Climesse?

Possible side effects and safety information

The official safety profile for Climesse (Estradiol and Norethisterone) is structured by classifying documented adverse reactions based on their frequency and the physiological system affected. The profile distinguishes between common effects and serious adverse reactions as defined in regulatory documents.

Frequency-Classified Adverse Reactions

Adverse reactions are categorized by their officially estimated frequency:

Very Common (ge 1 in 10): Reactions listed in this category include headache, breast pain or tenderness, and menstrual-like bleeding or spotting, which is often observed during the initial period of therapy.
Common (ge 1 in 100 to < 1 in 10): This category includes events such as nausea, abdominal pain, oedema (fluid retention), and dizziness.

Serious Adverse Reactions

Regulatory documentation highlights serious adverse reactions, which include the elevated risks for Venous Thromboembolism (VTE), Stroke, and Myocardial Infarction (heart attack). This medication is also associated with an increased risk of certain malignancies, including Breast Cancer, Endometrial Cancer, and Ovarian Cancer, as documented in official labeling.

Time-Related and Population Safety Notes

The incidence of certain effects is related to duration of exposure: breakthrough bleeding and spotting are documented as more common during the initial months of use (3 to 6 months), while the risk of VTE and malignancies is associated with long-term exposure.

Specific safety considerations exist for certain populations. The risk of probable dementia is officially increased when combination HRT is started in women aged 65 years or older. Furthermore, the medicine is contraindicated in individuals with severe hepatic impairment or a history of venous thromboembolism.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents state that acute over-ingestion of combined Estradiol and Norethisterone is classified as having low inherent toxicity, and severe, life-threatening outcomes are generally considered unlikely. Overdosage manifestations primarily affect the gastrointestinal and reproductive systems.

Documented clinical signs of overdosage include nausea, vomiting, breast tenderness or enlargement, abdominal pain, and subsequent vaginal bleeding (withdrawal bleeding). Other documented effects are drowsiness, fatigue, and fluid retention.

Immediate Emergency Actions

Immediate medical attention must be sought in the event of suspected overdose. No specific antidote is known for Estradiol and Norethisterone over-ingestion, and the required regulatory management is symptomatic and supportive treatment.

It is mandated to contact emergency services immediately if the affected person exhibits signs of severe compromise, such as collapse, seizure, trouble breathing, or inability to be awakened. Accidental ingestion by children also requires professional medical evaluation. Management procedures may involve the monitoring of vital signs, and in cases of excessively large acute ingestion, regulatory texts suggest procedures such as gastric lavage or activated charcoal may be considered.

Therapeutic Uses of Climesse

What Climesse Treats: Main Uses and Benefits

Climesse (Estradiol and Norethisterone combined therapy) is applied in addressing the symptoms related to systemic imbalance that follow menopause. This therapy is relevant in clinical settings that involve heightened systemic burden and often requires supportive symptom management. The medication is utilized across three main therapeutic domains, where it may assist with easing the overall symptom load and supports general well-being during symptomatic phases.

Key Therapeutic Focus

This combination is commonly used to help with the management of moderate to severe vasomotor symptoms, such as frequent hot flushes and disruptive night sweats. It is also applied in addressing bone density concerns by assisting with the management of accelerated bone loss, and is relevant for the treatment of symptoms of vulvar and vaginal atrophy. This therapy is often used when supportive symptom management is appropriate and may help patients cope more steadily with symptom fluctuations. Furthermore, this combined regimen is considered relevant in women with an intact uterus, and is used when supportive management is needed across conditions where functional stability becomes affected.

“This application contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Relief for Vasomotor Symptoms (Hot Flushes)

Regulatory References

National Institutes of Health (NIH) DailyMed

Eligibility and Restrictions for Use

Climesse is a Hormone Replacement Therapy (HRT) intended for use only in postmenopausal women who have had at least 12 months since their last natural menstrual period. Use in premenopausal women is not recommended.

Populations for Whom Use is Prohibited (Contraindications)

Climesse must not be used if you have any of the following conditions, as stated in official regulatory documents:

Known or suspected pregnancy or lactation (nursing women).
Known or suspected hormone-dependent cancers, such as breast cancer or oestrogen-dependent neoplasia.
Unexplained abnormal bleeding from the genital tract.
Active thrombophlebitis or thromboembolic disorders (e.g., blood clots in the legs or lungs).
Severe cardiac, hepatic (liver), or renal (kidney) disease.
Allergy to the active substances or any of the components.

Eligibility-Related Restrictions

Use is subject to special precaution or monitoring in patients with conditions such as uterine fibroids, endometriosis, a history of certain liver diseases, or a known increased risk of developing blood clots. Climesse is not a contraceptive and should not be used to prevent pregnancy.

What should I know about interactions with other medicines?

Official Interaction Profile

The interaction profile of Climesse (Estradiol and Norethisterone) is defined by pharmacokinetic changes mediated by liver enzymes and pharmacodynamic effects on co-administered medications, based strictly on regulatory documentation.

Interaction Type	Interacting Substance/Class	Official Interaction Statement
Formal Prohibition	Tranexamic Acid	This combination is a formally contraindicated or strongly not recommended co-administration due to the documented heightened risk of thrombosis.
Metabolic Induction	CYP3A4 Inducers (e.g., Carbamazepine, Phenytoin, Barbiturates)	Co-administration induces hormonal metabolism, leading to a decrease in plasma concentrations of Estradiol and Norethisterone.
Metabolic Inhibition	CYP3A4 Inhibitors (e.g., Ketoconazole, Grapefruit Juice)	Co-administration inhibits metabolism, leading to a resultant increase in the systemic exposure of the hormonal components.
Pharmacodynamic	Anticoagulant, Antidiabetic, and Antihypertensive Agents	Estradiol/Norethisterone may diminish the therapeutic effectiveness of these co-administered agents.
Herbal/Dietary	St. John's Wort (Herbal)	Classified as an enzyme inducer, resulting in decreased plasma concentration of the hormonal components.
Behavioral	Acute Alcohol Ingestion	May lead to documented elevations in circulating Estradiol levels.

Regulatory documents define the product’s interaction structure primarily through enzyme-mediated pharmacokinetic alteration via the CYP3A4 system, which dictates many exposure-modifying restrictions, and substance-specific pharmacodynamic prohibitions. These official statements identify substances that either increase or decrease the components' plasma levels or compromise the efficacy of co-administered medicines.

Mechanism of Action

Climesse is a fixed combination of estradiol valerate and norethisterone acetate, two synthetic steroid hormones. Upon oral administration, estradiol valerate is rapidly hydrolyzed to 17beta-estradiol, and norethisterone acetate is deacetylated to norethisterone (NET). Both compounds are distributed systemically and enter target cells, where they bind to their respective intracellular nuclear receptors: 17beta-estradiol acts as an agonist for the Estrogen Receptor ( ER) alpha and beta, and NET acts as an agonist for the Progesterone Receptor ( PR) A and B.

The ligand-receptor complexes dimerize, translocate to the nucleus, and bind to specific Hormone Response Elements ( HREs) on the DNA. This genomic interaction modulates the transcription of target genes, leading to changes in the synthesis of various cellular proteins. In the hypothalamus, this action modifies thermoregulatory center function. In the endometrium, the NET/PR complex induces secretory transformation and counteracts the proliferative effects mediated by the 17beta-estradiol/ER complex. System-level physiological modulation is characterized by changes in gene expression across multiple estrogen- and progesterone-responsive tissues.

Dosage and Administration Information

How to Use Climesse: Administration Guidelines

Climesse (estradiol and norethisterone) is a continuous combined Hormone Replacement Therapy (HRT) with established usage protocols. The primary route of administration is oral, delivered via a film-coated tablet. It is available in fixed-dose strengths, such as 1 mg/0.5 mg and 0.5 mg/0.1 mg of estradiol and norethisterone, respectively.

Dosing and Scheduling

The standard protocol mandates a continuous daily regimen, meaning the adult dosing schedule is one tablet once daily without interruption, to be taken every day of the month. To ensure consistency, the tablet should be administered at approximately the same time each day, and it may be taken with or without food. The continuous use pattern is a defining feature of this type of regimen.

Procedural Constraints

The treatment is typically initiated with the lowest available dose that is sufficient for the therapeutic goal. A key procedural instruction relates to missed doses: if a tablet is missed by more than 12 hours, the guidance is to discard the missed dose and resume the normal one-tablet-daily schedule, rather than taking two tablets. This instruction is tied to reducing the risk of potential breakthrough bleeding. Furthermore, the therapy is intended as a component of a long-term plan, necessitating periodic re-evaluation of continued use by a healthcare professional.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Climesse

This section outlines the structure of the clinical research and evidence base for Climesse, describing what types of studies have been conducted, what outcomes they monitored, and where research remains limited or ongoing. This overview focuses strictly on reported research patterns and contains no clinical advice or information on use, safety, or dosage.

Evidence for Use in Moderate to Severe Vasomotor Symptoms

The primary research exploring this continuous combined regimen was conducted as Randomized Controlled Trials (RCTs). These studies typically compared the therapy against a placebo in postmenopausal women with an intact uterus. Research examined outcomes related to physical discomfort, specifically the frequency and perceived severity of daily hot flushes and night sweats. Studies describe patterns observed in the measured frequency and severity of symptoms when research examined outcomes across all randomized groups over short-term periods (e.g., 12 weeks), which provided insight into short-term changes.

However, certainty remains low regarding how to directly compare findings across all available trials because the precise method for defining symptom severity varies across studies. Furthermore, long-term effects are not fully established through initial dedicated RCTs alone; evidence for sustained relief beyond one year is observed in some studies that integrate broader observational or safety surveillance research.

Evidence for Bone Health and Prevention of Accelerated Bone Loss

The evidence base for bone health includes dedicated Randomized Controlled Trials (RCTs) and Controlled Clinical Trials. These studies were applied in research contexts involving newly postmenopausal women to study outcomes related to bone loss, and older women with established postmenopausal osteoporosis. Research monitored changes in Bone Mineral Density (BMD) at key sites and shifts in bone turnover markers. Findings indicate patterns related to the BMD measured in the studied groups over defined time intervals (typically one to two years). Long-term data show patterns related to fracture incidence monitored in large studies, but this information is often derived from large-scale studies that included various hormonal therapy formulations.

Evidence in Specific Populations and Subgroups

Subgroup findings are uncertain, as there is limited information available from dedicated research that evaluated the therapy in certain special groups, such as those with highly specific comorbid conditions or those who are many years past menopause (e.g., very older adults). The main clinical trials focused on general, otherwise healthy postmenopausal women, meaning data for certain groups remain insufficient.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Climesse (FAQ)

Q: How quickly does Climesse start to relieve symptoms?

A: Regulatory studies suggest that some individuals may experience a reduction in the severity and frequency of vasomotor symptoms (such as hot flashes and night sweats) with treatment. Official clinical trials for this type of therapy often track this reduction within the first 4 to 8 weeks of starting the medication.

Q: How long does it take to see the full benefits of Climesse?

A: While initial symptom relief may be noticed within weeks, the therapeutic effects, particularly those related to the prevention of bone loss, are typically monitored over time, with studies often tracking changes over 1 to 2 years of continuous use. Due to this long-term approach, official guidance emphasizes the need for periodic re-evaluation.

Q: What are the signs that Climesse is actually working?

A: The primary clinical evidence of effect is a documented reduction in the frequency and severity of moderate to severe hot flashes and night sweats. Over time, the effects also include the prevention of accelerated bone loss associated with oestrogen deficiency.

Q: Do the side effects of Climesse usually go away after the first month?

A: Official product information notes that common side effects like unscheduled bleeding or spotting, headache, and breast tenderness are often observed initially. These symptoms are generally documented as more frequent during the first 3 to 6 months of treatment. Regulatory data suggests the incidence of these effects may decrease over time, but this is not guaranteed for every individual.

Q: Do you gain weight when taking Climesse?

A: According to regulatory documents, weight gain is listed as a documented adverse reaction that was observed during clinical trials or post-marketing surveillance. This is a possible outcome but is not universally experienced by all individuals taking the medication.

Q: Can Climesse make existing migraines worse?

A: While headache is a very common side effect of this therapy, official labeling advises caution for patients with a history of migraines. If unusually frequent or severe headaches, or new migraines, occur or worsen, regulatory guidance suggests treatment may need to be suspended pending investigation.

Q: Is there a link between Climesse and hair loss?

A: The official product labeling lists both hair loss (alopecia) and hirsutism (excessive hair growth) as documented, though typically uncommon, adverse reactions. These are included in the adverse event data reported from clinical trials or post-marketing surveillance.

Q: Does Climesse protect against osteoporosis?

A: Regulatory documentation indicates that Climesse is formally approved for the prevention of osteoporosis in specific postmenopausal women at high risk of fracture who have demonstrated intolerance to other treatment options. Studies show it can lead to an increase in bone mineral density (BMD).

Q: How long can someone safely stay on Climesse?

A: Official documentation advises that any hormone replacement therapy (HRT) should be used for the shortest duration consistent with the therapeutic goal. Due to documented risks associated with long-term exposure, the benefit-risk profile of the therapy should be regularly and periodically re-evaluated by a healthcare professional.

Q: What happens when you stop taking Climesse?

A: Discontinuation of hormone replacement therapy can lead to the recurrence of menopausal symptoms, such as the return of hot flashes and night sweats. The decision to discontinue treatment should be discussed with a healthcare professional.

Q: What is the usual dose of Climesse for menopausal symptoms?

A: Official guidance defines the standard regimen as continuous combined therapy administered orally. Dosage is typically initiated with the lowest effective dose necessary to achieve the therapeutic goal.

Q: What kind of studies have been done on the long-term use of Climesse?

A: Regulatory approvals rely on Randomized Controlled Trials (RCTs) for efficacy and long-term safety data derived from large-scale observational studies. These studies track risks such as cardiovascular events, thromboembolism, and malignancy over several years of use.

Q: Does Climesse help with vaginal dryness?

A: Regulatory information states that Climesse is indicated for the treatment of vulvar and vaginal atrophy, which is also referred to as the genitourinary syndrome of menopause. This condition includes symptoms such as dryness and painful intercourse (dyspareunia).

Q: Is Climesse a low-dose HRT option?

A: Climesse is available in fixed-dose strengths, including lower concentrations of the active ingredients. Its lowest concentration is generally considered a low-dose hormonal option compared to some standard HRT products.

Q: Do you need regular check-ups while taking Climesse?

A: Yes, official regulatory guidance requires a medical history and physical examination, including breast and pelvic examinations, before starting treatment. The therapy should be reviewed periodically (at least once a year) to assess the benefits and risks of continued use.

Q: Why is Climesse sometimes prescribed after a period of using sequential HRT?

A: Climesse is a continuous combined HRT, where both hormones are taken daily without interruption. This regimen is typically recommended for women who have already achieved amenorrhea (no period) on a sequential HRT, or for those who desire to eliminate the predictable monthly withdrawal bleeding associated with sequential therapy.

Q: Is Climesse considered a 'body-identical' HRT?

A: The formulation contains estradiol, which is chemically identical to the oestrogen produced naturally in the body. However, the second component, norethisterone acetate, is a synthetic progestogen, meaning the product is a combination of a body-identical oestrogen and a synthetic progestogen.

Q: What is the shelf life of Climesse tablets?

A: The shelf life of the product is officially indicated by the expiration date printed on the package. The medication must be kept in its original packaging and must not be used after this printed date.

Q: Can Climesse be used to treat perimenopausal symptoms?

A: Official regulatory documents state that Climesse is strictly indicated for use in postmenopausal women, defined as those who are at least 12 months from their last natural menstrual period. Use in women who are still in the perimenopausal phase is not recommended.

How should Climesse be stored and disposed of?

Storage Conditions

Climesse tablets must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). The official label permits brief temperature excursions between 15 C and 30 C (59 F and 86 F).

The medication must be protected from excess heat and moisture and should be kept in its original, tightly closed container.
It is mandatory to keep Climesse out of the sight and reach of children.
The product must not be used past the expiration date printed on the package.

Disposal Instructions

Unused or expired Climesse should be disposed of promptly. The regulatory preferred method is to use a community drug take-back program or mail-back envelope. If a take-back option is unavailable, the tablets can be discarded in the household trash by mixing them with an undesirable substance (e.g., dirt or coffee grounds) and sealing the mixture in a container. The product is not on the list of medicines recommended for flushing down the sink or toilet.

Climesse